A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

Top-line results were announced from a phase 3 trial evaluating nerandomilast an oral, investigational phosphodiesterase 4B inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF).

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...

4,5 Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is ...